Patent ID: 8962677
Filing Date: 2015-02-24
Classification: A61K,A61P

Abstract:
1. A method of enhancing cognitive function in a patient who has diminished cognitive function due to amyloid beta-derived diffusible ligand (ADDL) neurotoxicity which method comprises administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of 2-Hydroxy-benzoic acid [3-oxo-3-(1-methyl-1H-pyrazol-5-yl)-1-tritluoromethyl-prop-(Z)-ylidene]-hydrazide; 2-Hydroxy-benzoic acid [3-oxo-3-thiophen-2-yl-1-trifluoromethyl-prop-(Z)-ylidene]-hydrazide; 2-Hydroxy-benzoic acid [3-oxo-3-furan-2-yl-1-trifluoromethyl-prop-(Z)-ylidene]-hydrazide; N-(2-Methoxy-phenyl)-2-oxo-2-{N′-[3-oxo-3-thiophen-2-yl-1-trifluoromethyl-prop-(Z)-ylidene]-hydrazino}-acetamide; 2-{[1-(2-Hydroxy-3-methoxy-phenyl)-meth-(E)-ylidene-hydrazinooxalyl]-amino}-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester; 2-{[1-(2-Hydroxynaphthalen-1-yl)-meth-(E)-ylidene-hydrazinooxalyl]-amino}-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester; 2-{[1-(2-Hydroxyphenyl)-meth-(E)-ylidene-hydrazinooxalyl]-amino}-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester; 2-(3-ethyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide; 2-(5-hydroxy-3-propyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide; 2-(5-hydroxy-3-isopropyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide; 2-(5-hydroxy-3-isobutyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide; (5-hydroxy-3-propyl-5-(trifluoromethyl-4,5-dihydro-1H-pyrazol-1-yl)(2-hydroxyphenyl)methanone; N-(4-bromophenyl)-2-(3-ethyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoacetamide; 2-(5-hydroxy-3-propyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide; N-(4-bromophenyl)-2-hydroxy-3-propyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoacetamide; 2-(3-butyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide; 2-(5-hydroxy-3-isobutyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide; N-(4-bromophenyl)-2-(5-hydroxy-3-pentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoacetamide; 2-(5-hydroxy-3-pentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-oxoacetamide; 2-(5-hydroxy-3-isopentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide; 2-(5-hydroxy-3-isopentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-oxoacetamide; 2-(3-hexyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-oxoacetamide; 2-(3-cyclohexyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide; (E)-2-hydroxy-N′-((2-hydroxynaphthalen-1-yl)methylene)benzohydrazide; (E)-2-hydroxy-N′-((1-hydroxynaphthalen-2-yl)methylene)benzohydrazide; (E)-N′-(3,5-dibromo-2-hydroxybenzylidene)-2-hydroxybenzohydrazide; and (E)-N′-(5-bromo-2-hydroxybenzylidene)-2-hydroxybenzohydrazide.